Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announced the creation of a fully owned subsidiary in Belgium. The new office, located in Brussels South Biopark (Charleroi), is due to launch operations this month.
“We are very excited to be expanding our operations to Belgium, benefiting from local experience in growing biotech companies as well as starting a relationship with Belgian VCs and public investors,” said Marc Martinell, CEO of Minoryx.
Please find the press release hereRead more
Univercells announced today the commercial launch of its proprietary NevoLine™ bioproduction system for vaccines.
"This challenging two-year project aimed at delivering a new manufacturing system to drastically decrease cost, footprint and time to market for vaccine manufacturers, and we are pleased to have met these goals," Hugues Bultot, CEO and co-founder of Univercells said. "The NevoLine system is self-contained into a 6m² series of isolators. A facility designed with four NevoLine units would deliver up to 50 million sIPV doses per year for an estimated capital cost of $20M. These breakthrough achievements further strengthen our dedication to innovating flexible, scalable and accessible vaccines and biotherapeutics manufacturing solutions."
Discover the press release hereRead more